In vitro calcium oxalate crystallisation methods.

In vitro calcium oxalate crystallisation has been, and will continue to be, of fundamental importance to urolithiasis research. Many different methods have been employed which differ qualitatively and quantitatively in the extent that they reproduce aspects of the renal system or in their ability to distinguish different aspects of crystallisation activity. Whatever system is used there are three key aspects that are worth bearing in mind.

Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls?

Purpose: The BRI has been shown to discriminate between calcium oxalate stone formers and controls. BRI is the ratio of the concentration of ionized calcium and the amount of oxalate that must be added to 200 ml urine to initiate crystallization. Higher BRI values are predictive of being a stone former and a value of 1.

Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones.

Background: Alkaline citrate is thought to be helpful in reducing recurrences of calcium oxalate stones. The evidence for this is incomplete, there have been few good trials, all with their own limitations, and not all reported any significant benefit. In vitro studies are usually cited to support the clinical studies but these too have their drawbacks, in particular they relate to crystals and microscopic aggregates and not to actual stone growth.